Model-informed safety management of tocilizumab for pediatric sJIA: a PBPK approach for dose-escalation and vaccination timing

1

Tocilizumab is used to treat systemic juvenile idiopathic arthritis (sJIA), but optimal dosing and vaccine timing for children remain unclear.
2

A physiologically-based pharmacokinetic (PBPK) model was developed to predict the pharmacokinetics of tocilizumab in pediatric patients.
3

The model proposed dose-escalation strategies to reduce hypersensitivity reactions in children, particularly those under 2 years.
4

Live-attenuated vaccines should be administered 55 to 70 days after stopping tocilizumab, depending on disease activity monitoring.
5

PBPK modeling can inform precision drug treatment and vaccination regimens for pediatric patients with sJIA.